Publications by authors named "Jochen GleiSSner"

Claim this Profile
[
[Not Available].
Andreas Wiedemann, Andreas Manseck, Joachim Stein, Ruth Kirschner-Hermanns, Michael Froehner

Aktuelle Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Andreas Wiedemann, Andreas Manseck, Joachim Stein, Ruth Kirschner-Hermanns, Michael Froehner

Aktuelle Urol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
Carsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, Susanne Krege, Jürgen Gschwend

Prostate Cancer Prostatic Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Apalutamide in patients with high-risk M0CRPC: data from the pivotal SPARTAN study and initial experience from a compassionate use program].
Eva Hellmis, Christian Schwentner, Philipp Mandel, Séverine Banek, Jochen Gleißner

Aktuelle Urol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Apalutamide in patients with high-risk M0CRPC: data from the pivotal SPARTAN study and initial experience from a compassionate use program].
Eva Hellmis, Christian Schwentner, Philipp Mandel, Séverine Banek, Jochen Gleißner

Aktuelle Urol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Andreas Manseck, Alexander Piotrowski, Marius Butea-Bocu, Susan Foller, Jochen Gleissner

Procare· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
Carsten-Henning Ohlmann, Michelle Jäschke, Peter Jaehnig, Susanne Krege, Jürgen Gschwend

Prostate Cancer Prostatic Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial.
Natalya Benderska-Söder, Jan Hovanec, Beate Pesch, Peter J Goebell, Florian Roghmann, Jochen Gleissner

Urol Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial.
Henrik Suttmann, Jochen Gleissner, Andreas Huebner, Tim Mathes, Werner Baurecht

Cancers (Basel)· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Palliative care in an outpatient urological setting].
Jochen Gleißner

Aktuelle Urol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer.
Peyman Hadji, May Ziller, Tobias Maurer, Michael Autenrieth, Mathias Muth, Jochen Gleissner

J Bone Oncol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial.
Tim Schneider, Jochen Gleissner, Frank Merfort, Monika Hermanns, Manfred Beneke

J Sex Med· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis